Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

The OmniaSecure defibrillation lead, which Medtronic describes as “the world's smallest transvenous defibrillation lead,” has a size of just 4.7 French.

Medtronic’s OmniaSecure, the smallest ICD lead of its kind, linked to long-term durability

Reliability modeling suggests the small-diameter defibrillation lead, already linked to positive early outcomes, should last patients for at least 10 years—and likely longer. 

Video of Jamshid Maddahi, MD, UCLA, explaining why flurpiridaz will change cardiac imaging and increase the adoption of PET cardiac imaging.

A closer look at how FDA's flurpiridaz approval will impact nuclear cardiology

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

artificial intelligence in cardiology

FDA grants AI-powered ECG screening tool for aortic stenosis its breakthrough device designation

The FDA clearly sees significant potential in this new screening software from New York-based AccurKardia.

Banner ASC in Sun City, Arizona.

Low doses of radiation still increase risk of leukemia, lymphoma and myeloma

A new study found cumulative radiation exposure of 16 mSv to red bone marrow can cause an increased rate of some hematological malignancies.

AURORA trial results for Flurpiridaz F-18 PET vs. SPECT discussed by principal investigator Jamshid Maddahi, MD.

'This could be a paradigm shift': How PET with newly approved flurpiridaz compares to SPECT

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast/high frame rate myocardial contrast echocardiography

Ultrafast myocardial contrast echocardiography shows early potential to evaluate CAD

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Left, coronary CT angiography of a vessel showing plaque heavy calcium burden. Right, image showing color code of various types of plaque morphology showing the complexity of these lesions. The right image was processed using the FDA cleared, AI-enabled plaque assessment from Elucid.

FDA clears new software for AI-powered CCTA assessments

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

cardiologists evaluating the human heart to provide a treatment strategy

Rising heart failure, AFib rates a ‘wake-up call’ for US cardiologists

Today's heart teams already face a number of challenges on a day-to-day basis.  New data suggest they could soon be treating more patients than ever before.